Zevra Therapeutics

ISIN US4884452065

 | 

WKN A2QLX7

Market cap (in EUR)
604 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 604 m
EPS, EUR 0.79
P/B ratio 3.2
P/E ratio 12.8
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 94 m
Net income, EUR 69 m
Profit margin 72.87%

What ETF is Zevra Therapeutics in?

There are 3 ETFs which contain Zevra Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Zevra Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.06%
Equity
United States
Health Care
Biotech
72
Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Dist 0.02%
Equity
United States
Small Cap
3
WisdomTree Russell 2000 0.02%
Equity
United States
Small Cap
7
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.